CHRS — Coherus Oncology Share Price
0.000.00%
Last trade - 00:00- $93.91m
- $306.42m
- $266.96m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | 187.81 | ||
| Price to Sales | 0.48 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -89.87% | ||
| Return on Equity | n/a | ||
| Operating Margin | -52.79% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 475.82 | 326.55 | 211.04 | 257.24 | 266.96 | 55.09 | 111.44 | -5.6% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +32.12 | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Coherus Oncology, Inc., formerly Coherus BioSciences, Inc., is a fully integrated commercial-stage oncology company with an approved PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. LOQTORZI (toripalimab-tpzi) is its immuno-oncology franchise. LOQTORZI is the FDA-approved treatment indicated in combination with chemotherapy for recurrent or metastatic nasopharyngeal carcinoma (NPC) and is also in development for the treatment of additional tumor types. Its CHS-114 pipeline is a highly selective cytolytic CCR8 antibody that specifically binds and preferentially depletes CCR8+ tumor regulatory T cells (Tregs) with no off-target binding. Its Casdozokitug pipeline is a first-in-class, clinical-stage IL-27 antagonist, with demonstrated monotherapy activity in treatment-refractory NSCLC and clear cell renal cell carcinoma (ccRCC) and combination activity in hepatocellular carcinoma (HCC).
Directors
- Dennis Lanfear CHM (65)
- McDavid Stilwell CFO (50)
- Vladimir Vexler CSO (63)
- Thomas Fitzpatrick OTH
- Theresa LaVallee OTH (52)
- Mats Wahlstrom LED (66)
- Lee Newcomer DRC (69)
- Ali Satvat IND (43)
- Mark Stolper IND (49)
- Kimberly Tzoumakas IND (53)
- Last Annual
- December 31st, 2024
- Last Interim
- March 31st, 2025
- Incorporated
- September 29th, 2010
- Public Since
- November 6th, 2014
- No. of Shareholders
- 81
- No. of Employees
- 221
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- NASDAQ Global Market
- Shares in Issue
- 115,933,276
- Address
- C/O DENNIS M. LANFEAR, REDWOOD CITY, 94065
- Web
- https://www.coherus.com/
- Phone
- +1 6506493530
- Contact
- Jami Taylor
- Auditors
- Ernst & Young LLP
Upcoming Events for CHRS
Q3 2025 Coherus BioSciences Inc Earnings Release
Similar to CHRS
111
NASDAQ Global Market
ADMA Biologics
NASDAQ Global Market
ANI Pharmaceuticals
NASDAQ Global Market
Aquestive Therapeutics
NASDAQ Global Market
Avadel Pharmaceuticals
NASDAQ Global Market
FAQ
What is the Coherus Oncology share price?
As of Today at 20:00 UTC, shares in Coherus Oncology are trading at $0.81. This share price information is delayed by 15 minutes.
How has the Coherus Oncology share price performed this year?
Shares in Coherus Oncology last closed at $0.81 and the price had moved by -41.73% over the past 365 days. In terms of relative price strength the Coherus Oncology share price has underperformed the S&P500 Index by -47.9% over the past year.
What are the analyst and broker recommendations for Coherus Oncology?
The overall consensus recommendation for Coherus Oncology is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Coherus Oncology dividend yield?
Coherus Oncology does not currently pay a dividend.
Does Coherus Oncology pay a dividend?
Coherus Oncology does not currently pay a dividend.
When does Coherus Oncology next pay dividends?
Coherus Oncology does not currently pay a dividend.
How do I buy Coherus Oncology shares?
To buy shares in Coherus Oncology you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Coherus Oncology?
As of the previous close price of $0.81, shares in Coherus Oncology had a market capitalisation of $93.91m.
Where are Coherus Oncology shares listed?
Here are the trading details for Coherus Oncology:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: CHRS
What kind of share is Coherus Oncology?
Based on an overall assessment of its quality, value and momentum Coherus Oncology is currently classified as a Falling Star. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Coherus Oncology share price forecast for 2025?
The analyst consensus target price for shares in Coherus Oncology is $4.68. That is 477.78% above the last closing price of $0.81.
Analysts covering Coherus Oncology currently have a consensus Earnings Per Share (EPS) forecast of -$1.11 for the next financial year.
Find out moreWhat is the trend in the Coherus Oncology share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Coherus Oncology. Over the past six months, its share price has underperformed the S&P500 Index by -53.18%.
As of the last closing price of $0.81, shares in Coherus Oncology were trading -22.2% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Coherus Oncology PE Ratio?
The Coherus Oncology PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.81.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Coherus Oncology?
Coherus Oncology's management team is headed by:
- Dennis Lanfear - CHM
- McDavid Stilwell - CFO
- Vladimir Vexler - CSO
- Thomas Fitzpatrick - OTH
- Theresa LaVallee - OTH
- Mats Wahlstrom - LED
- Lee Newcomer - DRC
- Ali Satvat - IND
- Mark Stolper - IND
- Kimberly Tzoumakas - IND